Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Increase in Short Interest

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) saw a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 644,912 shares, a growth of 57.8% from the January 15th total of 408,588 shares. Currently, 2.0% of the shares of the company are short sold. Based on an average daily trading volume, of 246,539 shares, the days-to-cover ratio is presently 2.6 days. Based on an average daily trading volume, of 246,539 shares, the days-to-cover ratio is presently 2.6 days. Currently, 2.0% of the shares of the company are short sold.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. BML Capital Management LLC raised its stake in shares of Oramed Pharmaceuticals by 2.1% in the 2nd quarter. BML Capital Management LLC now owns 3,083,253 shares of the biotechnology company’s stock worth $6,937,000 after buying an additional 62,505 shares in the last quarter. Squarepoint Ops LLC raised its position in Oramed Pharmaceuticals by 95.1% in the fourth quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 28,406 shares in the last quarter. Marshall Wace LLP bought a new stake in Oramed Pharmaceuticals in the fourth quarter worth about $738,000. Jane Street Group LLC lifted its holdings in Oramed Pharmaceuticals by 31.2% in the 4th quarter. Jane Street Group LLC now owns 78,259 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 18,600 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Oramed Pharmaceuticals by 4.4% during the 3rd quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock valued at $395,000 after purchasing an additional 6,261 shares in the last quarter. 12.73% of the stock is currently owned by institutional investors and hedge funds.

Oramed Pharmaceuticals Price Performance

ORMP traded up $0.08 during trading on Monday, reaching $3.25. 62,934 shares of the stock were exchanged, compared to its average volume of 180,989. The company has a market capitalization of $129.35 million, a price-to-earnings ratio of 2.58 and a beta of 1.34. The business’s 50 day moving average price is $3.22 and its two-hundred day moving average price is $2.66. Oramed Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $3.71.

Oramed Pharmaceuticals Dividend Announcement

The business also recently disclosed a dividend, which was paid on Monday, January 26th. Investors of record on Friday, January 16th were paid a dividend of $0.25 per share. The ex-dividend date was Friday, January 16th. Oramed Pharmaceuticals’s dividend payout ratio (DPR) is currently 19.84%.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Wall Street Zen raised shares of Oramed Pharmaceuticals to a “hold” rating in a report on Saturday, November 1st. Weiss Ratings restated a “hold (c)” rating on shares of Oramed Pharmaceuticals in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.